Photo from wikipedia
Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin (IL)‐17A and IL‐17F, which is currently under investigation for treatment of moderate‐to‐severe plaque psoriasis. Maintenance dosing every 4 weeks is well… Click to show full abstract
Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin (IL)‐17A and IL‐17F, which is currently under investigation for treatment of moderate‐to‐severe plaque psoriasis. Maintenance dosing every 4 weeks is well established with IL‐17 inhibitors for psoriasis.
Keywords:
severe plaque;
plaque psoriasis;
treatment moderate;
moderate severe
Journal Title: British Journal of Dermatology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Dermatology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!